• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

0.9263 -0.0299 (-3.13%)
Official Closing Price Updated: 4:10 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
December 23, 2024
Via ACCESSWIRE
News headline image
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
November 27, 2024
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financial Progress and Advances Towards Key Phase II Clinical Trials
November 15, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
November 15, 2024
Via ACCESSWIRE
News headline image
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
October 08, 2024
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Advancements at Spartan Capital Investors Conference
November 04, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
November 03, 2024
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform and Drug Delivery Advances at PODD Conference
October 22, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides President Dr. Diwan to Present at the PODD Conference
October 22, 2024
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) CEO Featured in Latest Episode of PODD Podcast
October 15, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
October 15, 2024
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit
October 08, 2024
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K
September 30, 2024
Via Investor Brand Network
News headline image
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
September 30, 2024
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma
September 26, 2024
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
September 26, 2024
Via ACCESSWIRE
News headline image
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
August 26, 2024
Via ACCESSWIRE
News headline image
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
August 19, 2024
Via ACCESSWIRE
News headline image
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
August 08, 2024
Via ACCESSWIRE
News headline image
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
August 06, 2024
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?
August 02, 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 2, 2024) - Investorideas.com, a go-to investing platform covering biotech and... 
Via Newsfile
News headline image
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
August 01, 2024
Via ACCESSWIRE
News headline image
COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
July 24, 2024
Via ACCESSWIRE
News headline image
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
July 11, 2024
Via ACCESSWIRE
News headline image
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
July 01, 2024
Via ACCESSWIRE
News headline image
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
June 24, 2024
Via ACCESSWIRE
News headline image
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
June 20, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
June 20, 2024
 
Via Benzinga
News headline image
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model
June 20, 2024
Via ACCESSWIRE
News headline image
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
June 14, 2024
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap